UNSPSC 51141583: Tolgabide

This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0L55QF645F. European Medicines Agency schedules Tolgabide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11156MIG. Tolgabide generally arises in the molecular formula C18H18CL2N2O2.

UNSPSC 51141583 Tolgabide is a Commodity code under which state and local governments procure pharmaceutical products, primarily naloxone and safe drug deactivation systems for community health initiatives, as well as generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The recent solicitations show procurement focused on operational health and safety supplies, with issuing bodies including county health departments and state health and human services commissions, sometimes operating through multistate cooperative purchasing alliances that coordinate procurement across multiple participating jurisdictions.

Recent activity spans Florida and Minnesota, with the most concrete opportunity being Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023), which seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with awarded contracts effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs, indicating early-stage exploration of pharmacy benefit procurement models. The code shows activity concentrated in health agencies and multistate cooperative purchasing vehicles rather than fragmented across numerous small jurisdictions.